E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 9/8/2011 in the Prospect News PIPE Daily.

Raptor Pharmaceutical sets price for $40 million public sale of shares

Company sells common stock at $4.00 per share through JMP Securities

By Devika Patel

Knoxville, Tenn., Sept. 8 - Raptor Pharmaceutical Corp. said it priced its $40 million public offering of stock with a $6 million greenshoe. The deal was announced Sept. 7.

The company will sell 10 million common shares at $4.00 apiece, which is an 8.05% discount to the Sept. 7 closing share price of $4.35.

Settlement is expected Sept. 13.

JMP Securities LLC is the bookrunning manager, and Canaccord Genuity and Cowen and Co. are co-lead managers.

Proceeds will be used for the company's commercial and pre-commercial efforts, clinical and preclinical development programs and other general corporate activities.

Raptor is a Novato, Calif., biotechnology company that bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein and related proteins.

Issuer:Raptor Pharmaceutical Corp.
Issue:Common stock
Amount:$40 million
Greenshoe:$6 million
Shares:10 million
Price:$4.00
Warrants:No
Managers:JMP Securities LLC (bookrunner); Canaccord Genuity and Cowen and Co. (co-lead managers)
Announcement date:Sept. 7
Pricing date:Sept. 8
Settlement date:Sept. 13
Stock symbol:Nasdaq: RPTP
Stock price:$4.35 at close Sept. 7
Market capitalization:$145.3 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.